Welcome
Volition’s goal is to bring to market a range of epigenetic cancer detection blood tests.
There is an urgent and unmet need in the cancer diagnostic market for large scale and low cost screening tests. Inevitably, the chances of surviving cancer are greatly improved by early detection and diagnosis. There is currently no screening test for cancer in general, and very few effective mass screening tests for specific cancers.
VolitionRX Limited is quoted on the OTC Bulletin Board in the United States of America under the symbol VNRX.OB
|
|
Read more...
|
|
Nucleosomics™
Volition is currently developing a range of blood-based epigenetic cancer screening tests, which it aims to release for research then clinical use in Europe, North America and around the world.
The tests will enable doctors to:
- Screen for the general presence of cancer in the body with a single blood test
- Investigate which cancer is present in many of those cancer positive patients using a panel of tests
|
|
Read more...
|
|
VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
Singapore, May 14th, 2012… VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce the closure of a private placement of 582,510 shares at $1.75 per share (a total of US$$1,019,375.00 raised). The proceeds will in part be used to fund clinical trials of VolitionRX’s first NuQTM test kits.
|
|
Read more...
|
|
|
